Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of Single Ascending Dose of CAN106 in Healthy Subjects
NCT05095168Phase 1Completed
- Sponsor
- Care Pharmaceuticals
- Start
- Feb 2021
- Primary completion
- Nov 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in paroxysmal nocturnal hemoglobinuria (PNH) comparing Omoprubart (SAD) with Placebo (2 arms). Primary endpoints: Incidence of subjects with dose-limiting toxicity at 6 months, Incidence of adverse events at 6 months and 1 more. Started Feb 2021; status: completed.
02
Drugs
omoprubart
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT05095168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05095168.